Slide 1: ASX Announcement: Webinar Presentation: Diagnostics Deep Dive
ASX Announcement 20 March 2025 Webinar Presentation: Diagnostics Deep Dive Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a company at the forefront of microbiome diagnostics & therapeutics, is pleased to release the presentations for the Webinar, ‘Diagnostics Deep Dive’ to b
Slide 2: Diagnostics Deep Dive
For personal use only At the forefront of microbiome diagnostics & therapeutics Diagnostics Deep Dive ASX: MAP 20 MARCH 2025 Authorised for release by the Board of Directors
Slide 3: Disclaimer
Disclaimer 2 This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its a
Slide 4: Presenters
Presenters 3 For personal use only Luke Reid Eric Davis Chris Saad Lutz Krause Chief Executive Officer Chief Growth Officer Chief Product Officer Chief Scientific Officer
Slide 5: Today's deep dive agenda
Today’s deep dive agenda 4 Topic Presenter Executive Summary Dr. Luke Reid, CEO For personal use only The Microbiome Opportunity Dr. Luke Reid, CEO Why Microba? Dr. Luke Reid, CEO Our Diagnostics Strategy Dr. Luke Reid, CEO Problem Mr Chris Saad, CPO Solution Mr Eric Davis, CGO Market Assoc. Prof. L
Slide 6: Key Take Home Messages
Key Take Home Messages 5 • The market for this new diagnostic category of microbiome testing is potentially worth more than $100B For personal use only • Our focus today is patients with unresolved GI disease, a $25B market opportunity • 2 world leading products addressing these patients – MetaPanel
Slide 7: The Microbiome Opportunity
PART A: Diagnostics Opportunity, Products & Growth Strategy 6 For personal use only SECTION 1 The Microbiome Opportunity The next frontier in precision healthcare
Slide 8: Chronic diseases remain difficult to diagnose, treat, manage and cure
7 Chronic diseases remain difficult to diagnose, For personal use only treat, manage and cure Gastrointestinal Mental Cardiovascular Cancer Autoimmune Allergy
Slide 9: Chronic diseases represent over 90% of healthcare spend in the US
8 Chronic diseases collectively represent over 90% of healthcare spend in the US. For personal use only US$4 Trillion Ninety percent of the nation’s US$4.5 trillion in annual health care expenditures are for people with chronic and mental health conditions* Gastrointestinal Mental Cardiovascular Can
Slide 10: The gut microbiome is implicated in all of these conditions
9 The gut microbiome is implicated in all of these conditions. For personal use only 21,000+ Research publications demonstrate a clear link between chronic diseases and the gut microbiome* Gastrointestinal Mental Cardiovascular Cancer Autoimmune Allergy PubMed search terms "gut microbiome/microbiota
Slide 11: Changing the gut microbiome can treat chronic disease
10 Changing the gut microbiome can treat chronic disease. For personal use only 150+ Global clinical studies demonstrate that microbiome modulation can influence disease outcomes and clinical symptoms* Gastrointestinal Mental Cardiovascular Cancer Autoimmune Allergy PubMed search terms "gut microbio
Slide 12: Combating chronic disease through microbiome diagnostics and therapeutics
Combating chronic disease through microbiome 11 diagnostics and therapeutics $1.4 trillion healthcare disruption opportunity For personal use only Microbiome testing to diagnose and match patients Microbiome therapy to treat with the right treatment chronic diseases $125B Est. TAM $1.3T Est. TAM Man
Slide 13: Sonic Healthcare partnership quote
12 For personal use only “Our partnership with Microba exemplifies our commitment to invest in cutting edge developments in laboratory medicine. We see microbiome testing becoming a key part of pathology over coming years and are excited about the potential of this partnership and the opportunities
Slide 14: Why Microba?
13 For personal use only SECTION 2 Why Microba? The world's leading clinical Microbiome company
Slide 15: World's leading clinical microbiome company
Microba is the world’s leading clinical 14 Microbiome company - proven science & real patient outcomes For personal use only Deep bench of Clear, global & Family of Proprietary Impact and world-class ambitious mutually- technology - growth- leaders vision reinforcing powered oriented businesses flyw
Slide 16: Founded and operated by deep bench of world-class leaders
Founded and operated by deep bench of world-class leaders 15 For personal use only Prof. Gene Tyson Dr Luke Reid Mr James Heath Prof Trent Munro Dr Nicola Angel Dr David Wood Eric Davis Co-Founder Chief Executive Officer Chief Financial Officer SVP Therapeutics Laboratory Director Chief Technology O
Slide 17: Clear, global and ambitious vision
Clear, global and ambitious vision 16 For personal use only Broad-based Regular testing is Usage of approved Millions of patients acceptance commonplace therapeutics is living healthier lives The microbiome is High quality and routine Microbiome diagnostics recognised by clinically useful Microbiome
Slide 18: Family of mutually-reinforcing businesses
Family of mutually-reinforcing businesses 17 Diagnostics Supplements Therapeutics Clinical microbiome diagnostics Efficacious microbiome supplements Precision microbiome therapeutics For personal use only Multiple tests. Clinically formulated, evidence-based portfolio Data driven therapeutic develop
Slide 19: Proprietary microbiome dataset
Microba’s tests leverage the world's largest, clinically 18 applicable, proprietary microbiome dataset For personal use only • Broad-based species coverage Built from public genomes, proprietary genomes, and MAGs from 90,000+ global metagenomic samples. >100TB >90,000 of DNA data metagenomes coverin
Slide 20: Competitive Moat – Science & Data Flywheel
Competitive Moat 1 – Science & Data Flywheel 19 6. More Data Collection 1. The Most Proprietary Data More anonymous, proprietary World's largest, clinically For personal use only patient data applicable, proprietary microbiome dataset 5. More Engagement 2. More Clinical Utility More patients and Lea
Slide 21: Competitive Moat – Product Led Network Effects
Competitive Moat 2 – Product Led Network Effects 20 5. Increased retention 1. More Features For personal use only Increased retention, World-leading patient retesting, and clarity interpretability and collaboration for all stakeholders features 4. Improved 2. More Sharing Health Outcomes More patien
Slide 22: Microba's Diagnostics Strategy
21 For personal use only SECTION 3 Microba's Diagnostics Strategy A vision for improved patient health outcomes at scale
Slide 23: Solving real patient problems at the intersection of bits, biology and atoms
Solving real patient problems at the intersection 22 of bits, biology and atoms. For personal use only Software Science Ops GTM Patient Experiences Metagenomics Testing Kit Operations Brand + + + Clinician Experiences Molecular assays Lab Operations Direct Sales Bioinformatics Clinical Evidence Cust
Slide 24: The Diagnostic Problem
23 For personal use only SUB-SECTION 3.1 The Diagnostic Problem
Slide 25: Our diagnostics focus
24 Our diagnostics focus For personal use only Patients suffering from gastrointestinal disease Gastrointestinal Mental Cardiovascular Cancer Autoimmune Allergy → Focusing, and solving this first will then enable us to advance to the next problem
Slide 26: Why Gastrointestinal Disease?
Why Gastrointestinal Disease? 25 Millions of patients affected. Half are not getting a resolution For personal use only 37,310,000 47% Patients presenting annually in the US with lower GI abdominal symptoms* 21,500,000 53% Pain, bloating, other Resolved Unresolved 15,370,000 Diarrhoea 440,000 IBD %
Slide 27: The Diagnostic Solution
26 For personal use only SUB-SECTION 2.2 The Diagnostic Solution
Slide 28: Microba's current comprehensive diagnostic products
Microba’s current comprehensive diagnostic products 27 lead the market in addressing this problem head-on For personal use only First line Gastrointestinal pathogen test Launched March 2024 – Currently sold to Medical Clinicians Diagnosing pathogenic causes Stool DNA test. of GI symptoms 175 tar
Slide 29: Getting answers for patients in need
Getting answers for patients in need 28 Microba’s diagnostic products are closing the gap on GI symptom diagnosis and treatment For personal use only 100% 28% new insights with * 47% 50% ** Unresolved 24% new diagnoses with ** 0% % of patients achieving resolution of gastrointestinal symptoms after
Slide 30: Diagnostic Market Opportunity
29 For personal use only SUB-SECTION 3.2 Diagnostic Market Opportunity
Slide 31: A multi-billion dollar market opportunity
A multi-billion dollar market opportunity 30 For personal use only $25B+ Total Market Size* * Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims analysis for target patient populations, extrapolated Private and Medicaid numbers,
Slide 32: Customer flow and revenue model
31 For personal use only SUB-SECTION 3.3 Customer flow and revenue model
Slide 33: Customer flow and revenue model
Customer flow and revenue model 32 For personal use only Practitioner Patient orders test & Patient takes sample Lab processes test & referral receives sampling kit & returns to Microba delivers report • Patient presents to • Patient fulfills referral • Patient completes • Sample received by Practit
Slide 34: Product Deep Dive
33 For personal use only SUB-SECTION 3.4 Product Deep Dive
Slide 35: What Product means at Microba
Test Ops Making sure we At Microba, Product can quickly and reliably perform Exception Handling combines all disciplines of tests and deliver results Code that handles Science unexpected the business to deliver Making our test results accurate, situations gracefully For personal use only value to ma
Slide 36: Microba has two kinds of products
Microba has two kinds of products 35 Our Apps host and distribute our range of precision Tests the same For personal use only way YouTube apps host and distribute Videos. Apps Tests Patient App MetaXplore Clinician App PMS/EMR Integrations + MetaPanel [Next generation tests] Internal Tools ...
Slide 37: User Experience
User Experience 36 Multi-channel Continuous Patient & Easy-to-read Interactive Easy Sharing with Care Ordering Clinician Communication Reports Network For personal use only Clinician Web Portal PMS/EMR
Slide 38: Product Principles
Product Principles 37 Driven by Purpose We prioritise patient engagement, understanding and health outcomes above all else. We work to balance the For personal use only needs of a clinician's busy schedule and their need to apply their own clinical judgment. Therefore, we provide both easy to interp
Slide 39: Short-Term Product Strategy
Short-Term Product Strategy 38 Business For personal use only Objective Grow Testing Globally – 1 million Tests Primary Opportunity More useful More usable More accessible More visibility Supercharge Clinical Incredible Easy-to-use All tests purchasable in Increase Availability of Utility Kit Experi
Slide 40: Lightspeed high-level roadmap
Lightspeed high-level roadmap 39 Supercharging clinical utility one facet at a time For personal use only Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6 Readability Coverage Personalisation Actionability Patient Engagement Adherence Tracking Continuous Background Improvement Analytical Performance
Slide 41: Product Vision – A unified stack for all tests, markets & geos
Product Vision – A unified stack for all tests, markets & geos Unified Branding and Localisation For personal use only Unified Stand Alone & In-line Self-serve Education & Support Unified Distribution Integrations Unified Apps Suite Unified Tests Suite Unified Testing Kit Unified CRM & Test Operatio
Slide 42: Growth Deep Dive
41 For personal use only SUB-SECTION 3.5 Growth Deep Dive
Slide 43: GTM – Customer Roadmap
GTM – Customer Roadmap 42 For personal use only Phase 4 – Phase 5 – Hospitals & Patient Initiated Phase 1 – Phase 2 – Phase 3 – Healthcare with on-demand Clinicians Small Clinics Patient Activation networks clinician (B2B2C) (B2B2C) (B2C2B) (Enterprise) (B2C2B) Current Focus
Slide 44: GTM - Regions Roadmap
GTM - Regions Roadmap 43 For personal use only Phase 1 – Phase 2 – Phase 3 – Phase 4 – Phase 5 – Australia United Kingdom United States Italy Spain Current Focus
Slide 45: Growth Strategy
Growth Strategy 44 Our go-to-market model employs multiple tactics For personal use only Marketing 1st line & nurturing Engagement Direct Sales Face-to-face Education & Influencing Partners Extended Reach/Access, Credibility Events Access, Engagement, Credibility KOL Engagement & Advocacy Credibilit
Slide 46: Growth Stack - Channels & Tactics
Growth Stack - Channels & Tactics 45 Our channels and tactics will Phase 3 - Later grow aligned to the customer 1. Website For personal use only types we are targeting in a 2. 3. Direct Sales Outreach Educational Workshops and Webinars phased manner. Phase 2 - Next 4. Leveraging Key Opinion Leaders
Slide 47: Examples of Marketing & Sales Tools: MetaPanel
Examples of Marketing & Sales Tools 46 MetaPanel: One Test, 175 Answers - Detecting difficult-to-diagnose pathogens For personal use only MetaPanel Pathogen Target List Sample Report MetaPanel CC RWE White Paper Real-World Case Scenarios Doctors Brochure Patient Brochure
Slide 48: Examples of Marketing & Sales Tools: MetaXplore
Examples of Marketing & Sales Tools MetaXplore – enabling better informed clinical decisions for chronic GI disorders For personal use only Sales Deck Sample Report Demo Report Interpretation Clinical Webinars Microlearning Videos Support Tools Clinician Brochures Product Fact Sheets Patient Handout
Slide 49: Direct Sales Outreach – Deep Dive
Direct Sales Outreach – Deep Dive 48 Proactive medical best practice sales with partner leverage For personal use only Highly trained sales reps Channel Specific Expertise (IFM & Medical) Structured Sales Incentives Sales Commission + SPIFs An effective sales philosophy Challenger Model Leverage KOL
Slide 50: Direct Sales Outreach
Direct Sales Outreach 49 Active field sales, face-to-face engagement & proactive account management For personal use only
Slide 51: Partner collaboration
Partner collaboration 50 Working with our leading partners to build awareness, educate the market and drive adoption For personal use only “Occasionally, we see tectonic shifts in technology or testing platforms …”
Slide 52: Evidence Deep Dive
51 For personal use only SUB-SECTION 3.6 Evidence Deep Dive
Slide 53: Evidence generation roadmap
Evidence generation roadmap 52 For personal use only Phase 1 – Primary evidence for MetaPanel Phase 2 – Expanded evidence for MetaPanel Phase 3 – Evidence for additional target markets Current Focus Phase 1 – Primary evidence for MetaXplore Phase 2 – Expanded evidence for MetaXplore Phase 3 – Eviden
Slide 54: Evidence to support clinical adoption
Evidence to support clinical adoption 53 Our program of clinical studies is focused on delivering clinical evidence to drive behavior change in physicians, and enables reimbursement and guideline inclusion. For personal use only Study Product Patient Population Goal Patients Status Detection & Treat
Slide 55: Diagnostic Strategic Principles
54 For personal use only SUB-SECTION 3.7 Diagnostic Strategic Principles
Slide 56: Strategic Principles
Strategic Principles 55 • Establish Leadership: Define and own the new diagnostic category for microbiome testing, with intelligent For personal use only capital allocation to invest ahead of our growth • Deliver Scientific Credibility: Demonstrate real efficacy to build trust with clinicians and pa
Slide 57: When we succeed, our impact will be at the scale of these companies
When we succeed, our impact will be at the scale 56 of these companies. For personal use only Company What they do Why are they relevant Founded Investment Valuation Pioneered non-invasive pre-natal (NIPT) Opened a major new diagnostic category. 2008 $67.5M $0.62B diagnosis of generic abth This star